These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25034493)

  • 21. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
    J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular virology of hepatitis B virus.
    Locarnini S
    Semin Liver Dis; 2004; 24 Suppl 1():3-10. PubMed ID: 15192795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
    Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
    J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
    Alvarado-Esquivel C; de la Ascensión Carrera-Gracia M; Conde-González CJ; Juárez-Figueroa L; Ruiz-Maya L; Aguilar-Benavides S; Torres-Valenzuela A; Sablon E
    J Antimicrob Chemother; 2006 Feb; 57(2):221-3. PubMed ID: 16373428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
    Liu H; Mao R; Fan L; Xia J; Li Y; Yin Y; Li X; Zhao X; Guo H; Zhu H; Zhang Y; Kang Y; Zhang J
    J Virol Methods; 2011 Jul; 175(1):1-6. PubMed ID: 21513743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
    Kalayci R; Altindiş M; Gülamber G; Demirtürk N; Akcan Y; Demirdal T
    Mikrobiyol Bul; 2010 Apr; 44(2):237-43. PubMed ID: 20549958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
    Cento V; Van Hemert F; Neumann-Fraune M; Mirabelli C; Di Maio VC; Salpini R; Bertoli A; Micheli V; Gubertini G; Romano S; Visca M; De Sanctis GM; Berkhout B; Marino N; Mazzotta F; Cappiello G; Spanò A; Sarrecchia C; Ceccherini-Silberstein F; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
    J Infect; 2013 Oct; 67(4):303-12. PubMed ID: 23796863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.